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Increased glucose metabolism of inflammatory tissues is the
main source of false-positive 18F-FDG PET findings in oncology.
It has been suggested that radiolabeled nucleosides might be
more tumor specific. Methods: To test this hypothesis, we
compared the biodistribution of 3-deoxy-3-18F-fluorothymi-
dine (FLT) and 18F-FDG in Wistar rats that bore tumors (C6 rat
glioma in the right shoulder) and also had sterile inflammation in
the left calf muscle (induced by injection of 0.1 mL of turpen-
tine). Twenty-four hours after turpentine injection, the rats re-
ceived an intravenous bolus (30 MBq) of either 18F-FLT (n  5)
or 18F-FDG (n  5). Pretreatment of the animals with thymidine
phosphorylase (1,000 U/kg, intravenously) before injection of
18F-FLT proved to be necessary to reduce the serum levels of
endogenous thymidine and achieve satisfactory tumor uptake
of radioactivity. Results: Tumor-to-muscle ratios of 18F-FDG at
2 h after injection (13.2  3.0) were higher than those of 18F-FLT
(3.8  1.3). 18F-FDG showed high physiologic uptake in brain
and heart, whereas 18F-FLT was avidly taken up by bone mar-
row. 18F-FDG accumulated in the inflamed muscle, with 4.8 
1.2 times higher uptake in the affected thigh than in the con-
tralateral healthy thigh, in contrast to 18F-FLT, for which this ratio
was not significantly different from unity (1.3  0.4). Conclu-
sion: In 18F-FDG PET images, both tumor and inflammation
were visible, but 18F-FLT PET showed only the tumor. Thus, the
hypothesis that 18F-FLT has a higher tumor specificity was
confirmed in our animal model.
J Nucl Med 2004; 45:695–700
FDG labeled with 18F is currently the most widely used
radiopharmaceutical in clinical oncology. This analog of
glucose is trapped in tissues after phosphorylation by hexo-
kinase but is not a substrate for glycolysis. Although the
applications of 18F-FDG PET in tumor detection, staging,
and therapy evaluation are rapidly expanding, 18F-FDG
uptake is not tumor specific. Various forms of inflammatory
lesions also take up 18F-FDG and are a major cause of
false-positive results. Histologic confirmation of 18F-FDG–
positive lesions is therefore required for many types of
tumors (1–6). Macrophages, which invade tumors, espe-
cially after anticancer therapy, can induce high 18F-FDG
uptake as well and can complicate the interpretation of
18F-FDG PET images (1,7–9). Decreased uptake of 18F-
FDG is seen in hyperglycemic patients and can cause false-
negative results.
Another approach for tumor visualization is the use of
radiolabeled nucleosides such as 11C-thymidine. Because
11C-thymidine is rapidly incorporated into newly synthe-
sized DNA, this radiopharmaceutical can be used to image
cellular proliferation. Animal and in vitro studies have sug-
gested that thymidine uptake is considerable in malignant
tissue but much less in inflammatory cells than is 18F-FDG
uptake (10,11). Unfortunately, the imaging quality of 11C-
thymidine is relatively poor, and its clinical applications are
limited because of rapid in vivo degradation and the short
half-life of 11C (20 min) (12–14).
However, the pyrimidine analog 3-deoxy-3-fluorothy-
midine (FLT) can be labeled with 18F (half-life, 109.8 min)
and is resistant to metabolic breakdown (15). 18F-FLT is
transported by the same nucleoside carrier as is thymidine
and is also phosphorylated by the same enzyme, S-phase–
specific thymidine kinase 1, which leads to intracellular
trapping of radioactivity within the cytosol (16–21). In
contrast to thymidine, 18F-FLT remains in the cytosolic
fraction as 18F-FLT monophosphate and acts as a DNA
chain terminator because of the 3 substitution (17). Thus,
only a very slight DNA incorporation of 18F-FLT has been
observed in cell lines (18).
Although inflammatory cells display a high metabolic
activity and an avid uptake of 18F-FDG, they are recruited
from elsewhere and do not divide at the site of inflamma-
tion. Because the mitotic activity of inflammatory cells is
Received Sep. 23, 2003; revision accepted Dec. 2, 2003.
For correspondence or reprints contact: Philip H. Elsinga, PET Center,
Groningen University Hospital, P.O. Box 30001, 9700RB Groningen, The
Netherlands.
E-mail: p.h.elsinga@pet.azg.nl
SELECTIVITY OF 18F-FLT AND 18F-FDG • van Waarde et al. 695
low, these cells can be expected to show a relatively low
uptake of radiolabeled nucleosides. Thus, 18F-FLT may
overcome a major drawback of 18F-FDG imaging.
To the best of our knowledge, no studies comparing the
selectivity of 18F-FDG and 18F-FLT for tumor and inflam-
mation have been reported in the literature. Therefore, we
decided to examine the biodistribution of these radiopharma-
ceuticals in male Wistar rats that bore tumors and also had
sterile inflammation. The inflammation was induced by injec-
tion of turpentine, which is known to result in exudation of
plasma and migration of neutrophils within 24 h (22).
MATERIALS AND METHODS
Materials
18F-FLT was produced by radiofluoridation of the 2,3-anhydro-
5-O-(4,4-dimethoxytrityl)-thymidine precursor, with radiochem-
ical yields of 5%–10%. 18F-FDG was produced by the Hamacher
method (nucleophilic fluorination reaction followed by deprotec-
tion). The specific radioactivities of 18F-FLT and 18F-FDG were
always 10 (usually 50–100) TBq/mmol. Thymidine phosphory-
lase (from the bacterium Escherichia coli) was obtained from
Sigma. Matrigel basement membrane matrix was purchased from
BD Biosciences. Turpentine came from a local paint shop.
Animal Model
The experiments were performed by licensed investigators in
accordance with the Law on Animal Experiments of The Nether-
lands. Male Wistar rats (200- to 240-g body weight) were obtained
from Harlan. After the rats had been allowed 1 wk of acclimation,
C6 glioma cells (2  106, in a 1:1 v/v mixture of Matrigel and
Dulbecco’s minimal essential medium containing 5% fetal calf
serum) were subcutaneously injected into the right shoulder. Ma-
trigel was included to avoid migration of tumor cells to sites other
than the place of injection. Ten days later, 0.1 mL of turpentine
was intramuscularly injected into the thigh of the left hind leg.
After an additional 24 h, the radiopharmaceutical (either 18F-FDG
or 18F-FLT) was intravenously administered through a tail vein.
Phosphorylase Pretreatment
To reduce the serum levels of endogenous thymidine, 5 rats
were pretreated with thymidine phosphorylase (1,000–1,500 U/kg
of body weight) 45 min before injection of 18F-FLT. The enzyme
was administered by intravenous infusion through a tail vein.
Because phosphorylase is supplied in potassium phosphate buffer,
a slow rate of infusion was used (less than 50 L/min; total
volume, 0.6–1.0 mL) to avoid myocardial arrest. Plasma thymi-
dine was measured using reversed-phase high-performance liquid
chromatography (23,24).
Biodistribution Experiments
Twenty-four hours after the turpentine injection, the rats were
anesthetized using (S)-ketamine (50 mg/kg intraperitoneally) and
medetomidine (0.3 mg/kg intraperitoneally). The animals were
kept under anesthesia for the rest of the experiment. A bolus of
either 18F-FLT or 18F-FDG (0.3 mL containing 30 MBq) was
administered by intravenous injection through a lateral tail vein.
The rats were sacrificed 120 min after radiotracer injection by
extirpation of the heart (under general ketamine/medetomidine
anesthesia). Blood was collected, and normal tissues (brain, fat,
bone, heart, intestines, kidney, liver, lung, skeletal muscle, pan-
creas, spleen, submandibular salivary gland, and urinary bladder)
were excised. Urine was collected, and plasma and a red cell
fraction were obtained from blood centrifugation (5 min at
1,000g). The complete tumor was excised and carefully separated
from muscle and skin. Inflamed muscle was recognizable by its
pale color and could generally be distinguished from the surround-
ing darker tissue. A relatively small sample including the inflamed
region (0.71  0.32 g) was excised from the affected thigh. All
samples were weighed, and the radioactivity was measured using
a Compugamma CS 1282 counter (LKB-Wallac), applying a decay
correction. The results were expressed as dimensionless standard-
ized uptake values (dpm measured per gram of tissue/dpm injected
per gram of body weight). Tissue-to-plasma and tumor-to-muscle
concentration ratios of radioactivity were also calculated.
Histologic Examination of Inflamed Muscle and
C6 Tumors
Excised tumors and the inflamed parts of the thigh muscle were
fixed in formalin and embedded in paraffin. Sections 5 m thick
were stained with hematoxylin and eosin.
PET Imaging
Rats anesthetized with ketamine and medetomidine were placed
into a positron camera (ECAT 962/HR, 4.5 mm in full width at
half maximum; Siemens) and received a bolus injection of either
18F-FLT or 18F-FDG (30 MBq) through a tail vein. Data were
acquired from 90 to 150 min. A zoom factor of 1.5 was applied
during reconstruction (by filtered backprojection), and the matrix
size was 128  128.
Statistical Analysis
Statistical analysis was performed using the software package
Statistix (NH Analytic Software). Differences between the various
groups (18F-FLT, 18F-FLT with phosphorylase pretreatment, and
18F-FDG) were tested for statistical significance using the 2-sided
student t test for independent samples. P values  0.05 were
considered significant.
RESULTS
Development of Tumor and Inflammation
The growth rate of C6 tumors in Wistar rats proved to be
variable. Tumor mass at radiotracer injection was 1.61 
0.89 g (mean  SD; range, 0.41–2.97 g). Turpentine injec-
tion resulted in visible swelling of the inflamed thigh after
24 h, although the behavior of the rats during this period
was normal. The body weight of the animals during the
biodistribution experiments was 325  27 g.
18F-FLT Uptake in Untreated Rats
In initial experiments on 3 rats, the radiopharmaceutical
18F-FLT was administered directly to the animals without
any pretreatment. To our surprise, the nucleoside did not
accumulate above plasma levels in any organ except bone
marrow, small intestine, kidney, and urinary bladder (Table
1). Radioactivity did not accumulate even in the C6 tumors
(Table 2). High serum levels of endogenous thymidine may
have saturated tissue nucleoside transporters or thymidine
kinase 1 and have blocked uptake or trapping of 18F-FLT.
Anthony F. Shields (Karmanos Cancer Institute), Peter S.
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Conti, and James R. Bading (University of Southern Cali-
fornia) suggested that we infuse thymidine phosphorylase
before injection of 18F-FLT to circumvent this problem. The
next 5 rats were pretreated in this way; the radiolabeled
nucleoside was administered 45 min after the start of en-
zyme infusion. Data on untreated animals were compared
with data on the thymidine phosphorylase–pretreated group.
18F-FLT Uptake After Pretreatment
Pretreatment of animals with thymidine phosphorylase
(intravenously, 45 min before administration of the radio-
tracer) did not affect tissue-to-plasma ratios of 18F-FLT in
brain, adipose tissue, urinary bladder, heart, kidney, liver,
lung, normal and inflamed skeletal muscle, pancreas, or red
blood cells. However, infusion of the enzyme increased the
accumulation of 18F-FLT in bone, bone marrow, and the C6
tumor (Tables 1 and 2). Plasma levels of radioactivity
tended to decrease after phosphorylase infusion. Thus, tis-
sue-to-plasma ratios of radioactivity were significantly in-
creased in bone, bone marrow, intestines, tumor, spleen, and
submandibular salivary gland (data not shown). Tumor-to-
muscle ratios of radioactivity also significantly increased
TABLE 1
















Cerebellum 0.06  0.01 0.04  0.02 1.23  0.29 NS 0.001
Cortex 0.05  0.01 0.04  0.02 1.86  0.45 NS 0.001
Rest of brain 0.06  0.01 0.04  0.02 1.45  0.33 NS 0.001
Adipose tissue 0.14  0.16 0.03  0.02 0.09  0.04 NS 0.05
Urinary bladder 0.74  0.49 1.57  0.68 1.65  0.92 NS NS
Bone 0.19  0.03 1.18  0.67 0.35  0.11 0.06 0.09
Bone marrow 1.04  0.54 6.67  2.53 1.55  0.41 0.02 0.05
Heart 0.46  0.20 0.26  0.15 5.84  3.29 NS 0.02
Large intestine 0.54  0.25 0.55  0.16 1.37  0.32 NS 0.001
Small intestine 1.08  0.45 1.28  0.58 1.10  0.23 NS NS
Kidney 2.28  0.69 1.19  0.49 1.89  0.43 0.06 0.05
Liver 0.61  0.28 0.39  0.20 0.51  0.11 NS NS
Lung 0.46  0.16 0.34  0.19 1.15  0.26 NS 0.0005
Muscle 0.42  0.15 0.29  0.09 0.18  0.06 NS 0.05
Pancreas 0.41  0.21 0.26  0.12 0.32  0.05 NS NS
Plasma 0.58  0.25 0.31  0.15 0.43  0.17 NS NS
Red blood cells 0.55  0.21 0.31  0.15 0.31  0.09 NS NS
Spleen 0.56  0.20 1.16  0.63 1.64  0.42 NS NS
Submandibularis 0.31  0.11 0.34  0.17 1.18  0.30 NS 0.001
C6 tumor 0.55  0.06 1.14  0.62 2.34  0.72 NS 0.05
Inflammation 0.51  0.18 0.37  0.16 0.82  0.14 NS 0.002
Urine 12.6  2.0 16.3  12.4 9.0  2.0 NS NS
NS  not statistically significant.
The bone sample contained marrow; thus, bone uptake does not reflect defluorination.
TABLE 2
















Tumor-to-plasma ratio 1.0  0.4 3.8  1.4 6.1  2.7 0.05 NS
Tumor-to-muscle ratio 1.4  0.4 3.8  1.3 13.2  3.0 0.05 0.001
Inflammation-to-plasma ratio 0.9  0.1 1.2  0.3 2.1  0.8 NS 0.05
Inflammation-to-muscle ratio 1.2  0.0 1.3  0.4 4.8  1.2 NS 0.0002
Selectivity index* 1.8  1.7 10.6† 3.5  1.2
*Defined as (tumor uptake 	 muscle uptake)/(inflammation uptake 	 muscle uptake), that is, tumor-to-inflammation ratio corrected for
background activity.
†SD cannot be given because, in some animals, tracer uptake in inflamed muscle equalled that in contralateral healthy muscle.
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after phosphorylase treatment (Table 2). Plasma levels of
thymidine were measured in a parallel experiment on a
single rat and were found to decrease from 0.15 g/mL to
undetectable levels after phosphorylase infusion.
Biodistribution of 18F-FDG and 18F-FLT
The next 5 animals received 18F-FDG rather than 18F-
FLT, to compare the biodistribution of the 2 radiopharma-
ceuticals. The glucose analog 18F-FDG showed physiologic
uptake in heart and brain. 18F-FDG uptake was higher than
18F-FLT uptake in C6 tumors, inflamed muscle, brain, adi-
pose tissue, kidney, large intestine, lung, and submandibular
salivary gland (Table 1). In contrast, 18F-FLT accumulated
more in bone, bone marrow, and healthy muscle than did
18F-FDG (Table 1).
Selectivity of 18F-FDG and 18F-FLT
18F-FLT did not accumulate in inflammatory tissue (tis-
sue-to-plasma and tissue-to-muscle ratios were not signifi-
cantly different from unity). However, 18F-FDG accumula-
tion was 4.8-fold higher (P  0.0002) in inflamed thigh
muscle than in the noninflamed contralateral thigh (Table
2). The selectivity index (tumor-to-inflammatory tissue ratio
corrected for uptake in healthy muscle) was 10.6 for
18F-FLT and 3.5 for 18F-FDG (Table 2).
Tumor-to-plasma ratios of 18F-FLT and 18F-FDG were
not significantly different, but tumor-to-muscle ratios of
18F-FDG were significantly higher (P 0.001) than those of
18F-FLT (Table 2).
Histology of Inflamed Muscle and C6 Tumors
Histologic examination of the muscle specimens excised
24 h after turpentine injection showed an acute inflamma-
tory reaction. Massive infiltration of neutrophils was seen in
and between partially necrotic muscle fibers—the picture of
acute myositis (Fig. 1). In the border of the inflammatory
infiltrate, macrophages and few fibroblasts could be dis-
cerned.
Histologic examination of the excised C6 tumors showed
a malignant mesenchymal tumor (Fig. 2). Spindled tumor
cells with pleomorphic, hyperchromatic nuclei were ar-
ranged in short bundles. Many mitoses were found (range,
25–40 per 2 mm2). Small areas of tumor necrosis were seen,
composing less than 10% of the total tumor volume.
PET Images
PET images, obtained with the 2 tracers, of tumor- and
inflammation-bearing rats are shown in Figure 3. The head
of each animal is on the right, and the rats are seen from
below. Both 18F-FLT and 18F-FDG clearly revealed the C6
tumor in the right shoulder. 18F-FDG showed high, physi-
ologic uptake in the brain, in contrast to 18F-FLT. The
inflammation in the left hind leg was revealed with 18F-FDG
but not with 18F-FLT.
DISCUSSION
This study confirmed that the standardized uptake value
of 18F-FLT in inflammatory tissue is lower than that of
18F-FDG (Table 1; Fig. 3). Although the tumor uptake of
18F-FLT is also considerably lower than that of 18F-FDG
FIGURE 1. Microscopic image of a specimen of inflamed rat
muscle, 24 h after injection of turpentine (hematoxylin and eo-
sin, 400).
FIGURE 2. Microscopic image of a specimen of rat tumor,
11 d after inoculation of C6 cells (hematoxylin and eosin,400).
FIGURE 3. PET images obtained 110–130 min after injection
of 30 MBq of 18F-FLT (A) and 18F-FDG (B) into rats. 18F-FLT
reveals only the tumor, whereas both tumor and inflammation
are visible after injection of 18F-FDG.
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(Table 1), the selectivity of 18F-FLT for tumor versus in-
flammation is nevertheless higher than that of glucose ana-
log: 10.6- versus 3.5-fold at 120 min after injection, when
the data are corrected for background activity (Table 2).
Thus, the hypothesis that 18F-FLT has a higher tumor spec-
ificity was confirmed in our animal model.
Standardized uptake values of 18F-FDG in C6 tumors
were 2-fold higher than those of 18F-FLT. Tumor-to-muscle
ratios of 18F-FDG (13.2  3.0) were clearly superior to
those of 18F-FLT (3.8  1.3). These results are in accor-
dance with clinical data from 18F-FDG and 18F-FLT PET
scans, in which colorectal cancers have been found to dis-
play a 2-fold higher standardized uptake value of 18F-FDG
than of 18F-FLT (25).
However, 18F-FDG showed relatively poor selectivity for
distinguishing tumor from inflammatory tissue. The in-
flamed thigh was clearly visualized in a PET image (Fig. 3).
Tissue uptake of 18F-FDG was 4.8-fold greater in inflamed
muscle than in the contralateral healthy leg, and the selec-
tivity index of 18F-FDG for tumor versus inflammation was
3.5 (Table 2). Because only part of the volume of the
inflamed muscle samples consisted of neutrophils and mac-
rophages, 18F-FDG uptake in these inflammatory cells may
have been 10-fold greater than in normal muscle cells.
18F-FLT showed better tumor selectivity in our model
than did 18F-FDG. In a PET image (Fig. 3), the inflamed
thigh showed tracer uptake similar to that in the contralat-
eral healthy thigh. Biodistribution studies indicated that
accumulation of 18F-FLT in inflamed muscle was not sig-
nificantly different from that in noninflamed tissue of the
contralateral thigh (ratio, 1.3  0.4; Table 2). The selectiv-
ity index of 18F-FLT for tumor versus inflammation was
10.6 or greater (Table 2).
In Wistar rats, the glucose analog showed a biodistribu-
tion that was expected on the basis of clinical 18F-FDG PET
scans, that is, high and physiologic uptake in brain and
heart, besides renal excretion and accumulation in urine
(Table 1). In contrast to 18F-FDG, 18F-FLT accumulated
mainly in bone marrow (Table 1). Low levels of radioac-
tivity in the brain were probably due to the slow transpor-
tation of 18F-FLT across the blood–brain barrier or to the
low activity of thymidine kinase in the brain.
The data presented in the tables indicate that endogenous
thymidine can strongly affect in vivo uptake of 18F-FLT.
Low tissue uptake of 18F-FLT in untreated rats is probably
a consequence of high levels of endogenous thymidine in
rodent serum (26), since previous infusion of thymidine
phosphorylase significantly increased uptake of the radiola-
beled nucleoside in target organs (Table 1). Thymidine may
compete with 18F-FLT for the active site of nucleoside
carriers in cell membranes (27) and also for the active site
of the trapping enzyme, thymidine kinase 1. The affinity of
human thymidine kinase 1 for thymidine has been reported
to be 4-fold higher (0.5 mol/L) than is the affinity for
18F-FLT (2.1 mol/L) (21).
Apparently, substantial plasma concentrations of endog-
enous thymidine can suppress 18F-FLT uptake in most tis-
sues (Table 1). In contrast to rats, humans have much (9- to
16-fold) lower levels of serum thymidine (0.01–0.02
g/mL vs. 0.15–0.27 g/mL) (26). Therefore, 18F-FLT PET
scans of cancer patients show adequate image contrast
(19,20,25,28,29).
After infusion of a thymidine-degrading enzyme, physi-
ologic accumulation of 18F-FLT to levels greater than those
in plasma was observed in C6 tumors, bone, bone marrow,
large and small intestine, and spleen (Table 1). Many of
these organs contain rapidly dividing tissue (malignant cells
in the tumor, bone marrow in the skeleton, mucosa in the
intestines). Thus, in pretreated rats, 18F-FLT behaved as a
tracer of cellular proliferation. This finding is in accordance
with reports from the literature suggesting a significant
correlation between standardized uptake values of 18F-FLT
and proliferative activity of various lesions (28,30,31). In
vitro studies have shown that 18F-FLT uptake is related to
thymidine kinase-1 activity and the percentage of cells in
S-phase (16,17). 18F-FDG accumulated in the same rapidly
dividing tissues as did 18F-FLT (Table 2) and showed even
higher standardized uptake values in tumor and large intes-
tine.
CONCLUSION
In our animal model, 18F-FLT revealed only tumor,
whereas 18F-FDG delineated both tumor and inflammation.
On the basis of these animal data, 18F-FLT scans of onco-
logic patients can be expected to show more false-negative
findings (because of lower tumor uptake) and fewer false-
positive findings (because of negligible accumulation in
granulocytes) than do whole-body 18F-FDG scans.
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